DexCom earnings beat by $0.03, revenue topped estimates
GeoVax Labs, Inc. (NASDAQ:GOVX) President and CEO, David A. Dodd, has increased his stake in the company by acquiring 10,000 shares of common stock. The transaction, which took place on April 1, 2025, was executed at a price of $1.08 per share, amounting to a total investment of $10,800. Following this purchase, Dodd now holds 36,661 shares directly. The purchase comes as the stock trades near its 52-week low of $1.06, with analyst price targets ranging from $8 to $20. According to InvestingPro analysis, the company currently holds more cash than debt on its balance sheet. This move underscores Dodd’s continued confidence in the company’s prospects as it advances its work in the pharmaceutical sector. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report, which provides deep-dive analysis of this and 1,400+ other US stocks.
In other recent news, GeoVax Labs Inc. reported its financial results for the full year 2024, revealing a net loss of $25 million, or $4.82 per share, on revenues of $4 million, primarily from its BARDA contract. The company has been focusing heavily on research and development, with expenses increasing by 14% to $23.7 million. GeoVax’s cash balance was reported at $5.5 million as of December 31, 2024. The company is planning to initiate clinical trials for its COVID-19 vaccine, CM04S1, and its MPOX vaccine in the near future.
GeoVax continues to explore strategic partnerships and funding strategies to support its development programs. The company’s future guidance includes the initiation of clinical trials for its COVID-19 vaccine CM04S1 in late 2024 or early 2025. Analyst firms have not provided recent upgrades or downgrades, but the company’s ongoing financial challenges and strategic initiatives are being closely monitored by investors. The company is also addressing potential delays in clinical trials and competitive pressures in the vaccine market. These developments come amid ongoing discussions with international health organizations and continued support from BARDA.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.